SPARC Aggravates Blood-Brain Barrier Disruption via Integrin αVβ3/MAPKs/MMP-9 Signaling Pathway after Subarachnoid Hemorrhage

Figure 7

Effects of a recombinant secreted protein acidic and rich in cysteine (rSPARC) and an integrin αVβ3 inhibitor at 24 h after modeling. (a) rSPARC exacerbates modified Garcia’s score and inhibition of integrin αVβ3 suppresses the effects of rSPARC after SAH ( per group). and . (b) Representative Western blot images and densitometric quantification of expression of phosphorylated p46 and p54 c-Jun N-terminal kinase (p-JNK), phosphorylated p38 (p-p38), interleukin (IL)-6, pro and active matrix metalloproteinase (MMP)-9, ZO-1, and vascular endothelial- (VE-) cadherin. Representative Western blots come from the same samples but multiple membranes. Expression levels of each protein are assessed using β-actin as an internal control: the levels are expressed as the target protein/β-actin, p-p38/p38, or p-JNK/JNK and as a ratio of the average level of the sham + PBS group for normalization, because the levels of p38 and JNK are unchanged among the groups (; per group). and vs. sham + phosphate-buffered saline (PBS), ^† and ^‡ vs. Sham + rSPARC, ^§ and ^¶ vs. SAH + PBS, ^# and ^## vs. SAH + rSPARC. cRGD: cyclo(-RGDfK): integrin αVβ3 inhibitor.

(a)

(b)